OVERVIEW

Optimizing Personalized Care Plans for Patients With Advanced Non-Small Cell Lung Cancer is organized by i3 Health.

Release: February 19, 2020
Expiration: February 18, 2021

Accreditation:
Physicians:
i3 Health designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.

MOC:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Physician Assistants:
Physician assistants may receive a maximum of 1.5 hours of Category 1 credit for completing this program.

Continuing Nursing Education:
A maximum of 1.5 contact hours may be earned by learners who successfully complete this continuing nursing education activity. This activity has been designated for 0.8 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.5 contact hours.

Statement of Need:
An estimated 228,150 new cases of lung cancer are reported in the United States annually, and 142,670 people die of the disease. The major subtypes are non-small cell (84%) and small cell (13%). Most patients with lung cancer are diagnosed at a locally advanced or metastatic stage, making systemic therapy the cornerstone of management. Although 70% of patients receiving first-line classical doublet chemotherapy demonstrate clinical benefit, most develop progressive disease within 5 months of their final cycle. Recently, the use of tumor histology in determining optimal treatment strategies and relevant molecular biomarkers to further refine selection of novel therapies has improved outcomes for some patients. However, the 5-year survival rates remain dismal for both non-small cell (18%) and small cell lung cancer (5% to 10%), indicating a need for continued research on more effective approaches to tumor control.

Learning Objectives:
Upon completion of this activity, participants should be able to:
• Assess predictive and prognostic markers that can inform personalized care plans for patients with advanced NSCLC
• Evaluate current and emerging data on first-line, second-line, and salvage therapy for patients with advanced NSCLC
• Apply strategies to manage adverse events and optimize treatment outcomes of patients with advanced NSCLC

Note: The learning objectives listed above apply to nurse practitioners and registered nurses in addition to physicians.

Faculty:
• Mark A. Socinski, MD, Executive Medical Director, AdventHealth Cancer Institute
• Maureen F. Zakowski, MD, Anatomic Pathology, The Mount Sinai Hospital
• Victoria Sherry, DNP, CRNP, AOCNP®, Oncology Nurse Practitioner, Abramson Cancer Center